In This Section

Program

Please note that this meeting will take place as an in-person event in Philadelphia and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

[R] – Remote Presentation

TUESDAY, JANUARY 13

WEDNESDAY, JANUARY 14

THURSDAY, JANUARY 15

Tuesday, January 13

registration

3-7 p.m. | Grand Ballroom Foyer

Welcome and Keynote Lectures 

4-6 p.m. | Grand Ballroom ABC

Session Chair: Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts

  • 4:15 p.m. | Gene fusions in sarcomas, from genetics to immunology
    Olivier Delattre, Institute Curie, Paris, France
  • 5 p.m. | Arul Chinnaiyan, University of Michigan, Ann Arbor, Michigan

Break

5:45-6 p.m. | Grand Ballroom Foyer

Plenary Session 1: Fusion oncogenes—Discovery to treatment

6-7 p.m. | Grand Ballroom ABC

Session Chair: Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts

  • 6 p.m. | Fusion oncogenes: Discovery to treatment – A pathologist experience
    Cristina Antonescu, Memorial Sloan Kettering Cancer Center, New York, New York
  • 6:30 p.m. | Sandy Simon, The Rockefeller University, New York, New York

Opening Reception and Poster Session A 

7-9 p.m. | Grand Ballroom D

Wednesday, January 14

breakfast

7-8 a.m. | Grand Ballroom Foyer

Plenary Session 2: Genetics, cellular origins, and model systems

8-10 a.m. | Grand Ballroom ABC

Session Chair: Mark Hatley, St. Jude Children’s Research Hospital, Memphis, Tennessee

  • 8 a.m. | Developmental reprogramming in the origin of pediatric fusion oncogene sarcomas
    Jim Amatruda, Children’s Hospital of Los Angeles, Los Angeles, California
  • 8:30 a.m. | Modeling genetic, epigenetic and developmental heterogeneity in fusion-driven pediatric AML
    Jeffrey MaGee, Washington University School of Medicine, St. Louis, Missouri
  • 9 a.m. | Mark Hatley
  • 9:30 a.m. | TFE3 fusions link tryptophan metabolism to AhR activation in tRCC: a targetable vulnerability*
    Xiang Li, The University of Texas Southwestern Medical Center, Dallas, Texas
  • 9:45 a.m. | Domain-specific oncogenic functions of VGLL2::NCOA2 in infantile rhabdomyosarcoma*
    Chinmay Sankhe, Nationwide Children’s Hospital, Columbus, Ohio

Break

10-10:30 a.m. | Grand Ballroom Foyer

Plenary Session 3: Mechanism Based Therapeutics

10:30 a.m.-12:30 p.m. | Grand Ballroom ABC

Session Chair: Ross A. Okimoto, University of California San Francisco, San Francisco, California

  • 10:30 a.m. | Scott Armstrong, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 11:15 a.m. | Fusion proteins in CIC-DUX4 and Ewing sarcomas: Novel mechanisms and targeting approaches
    Hua Yu, City of Hope National Medical Center, Duarte, California
  • 11:45 a.m. | Targeting replication stress and cell cycle checkpoint to overcome CIC-rearranged sarcomas
    Ross A. Okimoto
  • 12:15 p.m. | KLIPP: Targeting fusion oncogenes with CRISPR*
    Mats Ljungman, University of Michigan, Ann Arbor, Michigan

Lunch on own

12:30-2:30 p.m.

Plenary Session 4: Condensates: Fact or Fusion?

2:30-4:15 p.m. | Grand Ballroom ABC

Session Chair: Natasha Caplen, National Cancer Institute, Bethesda, Maryland

  • 2 p.m. | Modulating fusion oncoprotein condensates to treat cancer
    Danfeng Cai, Johns Hopkins University, Baltimore, Maryland
  • 2:30 p.m. | Low-order multimers drive RTK fusion activity without condensation
    Lukasz Bugaj, University of Pennsylvania, Philadelphia, Pennsylvania
  • 3 p.m. | Biocondensates in action: The formation and reformation of EWSR1, FUS and TAF15 ribonucleoprotein networks
    Natasha Caplen, National Cancer Institute, Bethesda, Maryland
  • 3:30 p.m. | Miguel Rivera, Massachusetts General Hospital, Boston, Massachusetts
  • 4:00 p.m. | Drugging condensates in fusion-positive cancers with an integrated discovery platform*
    Andrew Seeber, Transition Bio, Somerville, Massachusetts

Break

4:15-4:30 p.m. | Grand Ballroom Foyer

Plenary Session 5: Translating Discoveries toward New therapies

4:30-6:30 p.m. | Grand Ballroom ABC

Session Chair: Jolanta Grembecka, University of Michigan, Ann Arbor, Michigan

  • 4:30 p.m. | Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, New York
  • 5 p.m. | Targeted menin inhibition to disrupt leukemia fusion oncoproteins: From discovery to therapeutic applications
    Jolanta Grembecka
  • 5:30 p.m. | Advances in ALK fusion-positive lung cancers
    Jessica Jiyeong Lin, Massachusetts General Hospital, Boston, Massachusetts
  • 6 p.m. | NUT carcinoma: myths, mysteries, and momentum
    Jia Luo, Dana-Farber Cancer Institute, Boston, Massachusetts

Lightning Talks

6:30-7 p.m. | Grand Ballroom ABC

  • Exploiting the dependency on DDX19A to induce transcriptional catastrophe in Ewing sarcoma
    Saikat Chakraborty, St. Jude Children’s Research Hospital, Memphis, Tennessee
  • Low-order assemblies drive RTK fusion signaling without condensation
    David Gonzalez-Martinez, University of Pennsylvania, Philadelphia, Pennsylvania
  • Fetal differentiation programs afford a protective barrier to NUP98 fusion-driven AML initiation
    Jihye Yoon, Washington University School of Medicine, St. Louis, Missouri
  • Deciphering the developmental epigenetic programs at risk of brain cancer
    Alisa Kardian, St. Jude’s Children’s Research Hospital, Memphis, Tennessee
  • Uncovering novel molecular vulnerabilities in PICALM::MLLT10 driven pediatric acute myeloid leukemia
    Lauren J. Ezzell, St. Jude’s Children’s Research Hospital, Memphis, Tennessee
  • PAX3::FOXO1-targeting PROTACs in fusion-positive rhabdomyosarcoma
    Nikola Knoll, Georgetown University, Washington, DC
  • YAP1::TFE3 fusion protein promotes transformation and EndMT plasticity in epithelioid hemangioendothelioma
    Jason Hanna, Purdue University, West Lafayette, Indiana

Reception and Posters B

7-9 p.m. | Grand Ballroom D

Thursday, January 15

breakfast

7-8 a.m. | Grand Ballroom Foyer

Plenary Session 6: Gene Regulatory Mechanisms of Oncoproteins

8-10 a.m. | Grand Ballroom ABC

Session Chair: Eleni Tomazou, St. Anna Children’s Cancer Research Institute, Vienna, Austria

  • 8 a.m. | Mechanisms of ZFTA- Fusion driven cancer
    Stephen Mack, St. Jude Children’s Research Hospital, Memphis, Tennessee
  • 8:30 a.m. | Fusion-driven sarcomas: From epigenetic profiling to unexplored vulnerabilities
    Eleni Tomazou
  • 9 a.m. | WWTR1(TAZ)-CAMTA1 gene fusion in epithelioid hemangioendothelioma, a sarcoma with endothelial differentiation that is vulnerable to CDK9 inhibition
    Brian Rubin, Cleveland Clinic, Cleveland, Ohio
  • 9:30 a.m. | Targeting chromatin–cell-cycle vulnerabilities in high-risk pediatric acute myeloid leukemia*
    Gabriel Boyle, Seattle Children’s Research Institute, Seattle, Washington
  • 9:45 a.m. | CBFA2T3–GLIS2 fusion reprograms enhancer-linked DNA methylation to enforce apoptotic resistance and defines an epigenetic vulnerability in pediatric AML*
    Samrat Roychowdhury, University of Arkansas for Medical Sciences, Little Rock, Arkansas

Break

10-10:30 a.m. | Grand Ballroom Foyer

Plenary Session 7: Discovery of new targets with Functional and Chemical Genomics

10:30 a.m.-12:45 p.m. | Grand Ballroom ABC

Session Chair: David McFadden, University of Texas Southwestern Medical Center, Dallas, Texas

  • 10: 30-11:00 a.m. | Reimagining druggability using chemoproteomic platforms
    Daniel Nomura, University of California Berkeley, Berkeley, California
  • 11 a.m. | David McFadden
  • 11:30 a.m. | Targeting fusion-driven cancers
    Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 12 p.m. | Fusion partners as novel therapeutic opportunity for fusion-positive cancer
    Sean Misek, Dana-Farber Cancer Institute, Boston, Massachusetts

Closing Remarks

12:30 p.m.